Braskem S.A.

Fundamentals2.0
Price Action3.0
News Sentiment4.0
AI Rating
3.0

Key Drivers

  • Thin Margins
  • Heavy Leverage
  • Weak Liquidity

AI
AI Summary

3.0

BAK should be viewed primarily as a distressed balance-sheet/restructuring story rather than a normal cyclical recovery, because the Q2 EBITDA rebound looks temporary while high leverage, weak liquidity, and negative equity mean any cash generation only matters if it materially reduces debt or supports a balance-sheet reset before spreads normalize.

Restructuring
DebtRisk
Cyclicals‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

2.0

Key Financial Insights:

  • Thin Margins
  • Heavy Leverage
  • Weak Liquidity

BAK is a highly distressed, leverage-heavy business with large revenue scale but thin margins, negative equity, weak liquidity, and negative free cash flow despite some operating cash generation.

distressed
leverage

Price Behavior

3.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Failed rebounds
  • Key support break

BAK remains in a clear bearish downtrend over the last month, with lower highs, failed rebounds, and $2.30-$2.33 now acting as resistance while $1.95 is the key support.

bearish
oversold
Support Level: $1.95
Resistance Level: $2.30-$2.33

Sharp drop from $2.46 to $1.95 with repeated weak rebounds signals sustained downside pressure

Sentiment & News

4.0

Key News Insights:

  • EBITDA lift
  • Restructuring pressure
  • Bio-acetone push

Braskem's Q2 earnings improved on wider spreads, but the upside looks temporary amid petrochemical oversupply, restructuring pressure, and selective diversification efforts.

Restructuring

The news may provide near-term support, but ongoing balance-sheet and industry-cycle risks likely limit sustained upside